These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. Schölzel-Dorenbos CJ Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117 [No Abstract] [Full Text] [Related]
3. Third drug to treat Alzheimer's approved. Mayo Clin Health Lett; 2000 Aug; 18(8):4. PubMed ID: 10932951 [No Abstract] [Full Text] [Related]
4. Rivastigmine for Alzheimer's disease. Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350 [TBL] [Abstract][Full Text] [Related]
5. Rivastigmine (Exelon) for Alzheimer's disease. Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159 [No Abstract] [Full Text] [Related]
6. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333 [TBL] [Abstract][Full Text] [Related]
7. Featured CME topic: dementia. Medication update. Slagle MA South Med J; 2001 Jul; 94(7):678-81. PubMed ID: 11531174 [No Abstract] [Full Text] [Related]
8. Science commentary: rational drug design for Alzheimer's disease. Berger A BMJ; 1999 Mar; 318(7184):639. PubMed ID: 10215361 [No Abstract] [Full Text] [Related]
10. Rivastagmine-induced agitation following transient recollection of autobiographical memory. Caffarra P; Majer S; Godani M; Paolello P Neurol Sci; 2001 Jun; 22(3):279-80. PubMed ID: 11731885 [No Abstract] [Full Text] [Related]
11. The impact of journal advertisements on prescribers of cholinesterase inhibitors. Sauer J; Howard R Int J Geriatr Psychiatry; 2002 Oct; 17(10):976-8. PubMed ID: 12325061 [No Abstract] [Full Text] [Related]
12. Commentary: Another piece of the Alzheimer's jigsaw. Bayer T BMJ; 1999 Mar; 318(7184):639. PubMed ID: 10215360 [No Abstract] [Full Text] [Related]
14. Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed. Selai CE; Trimble MR; Rossor MN; Harvey RJ BMJ; 1999 Sep; 319(7210):641-2. PubMed ID: 10523095 [No Abstract] [Full Text] [Related]
15. Rivastigmine in the treatment of alcohol-induced persisting dementia. Gibson RC; Barnaby L West Indian Med J; 2003 Mar; 52(1):59-61. PubMed ID: 12806761 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of rivastigmine in Alzheimer's disease. Guidelines do not ignore clinically relevant end points. Storosum JG; van Zwieten-Boot BJ; Elferink AJ BMJ; 1999 Sep; 319(7210):642. PubMed ID: 10523096 [No Abstract] [Full Text] [Related]
17. [Cholinesterase inhibitors in Alzheimer disease; preliminary recommendations for the practice]. Van Zwieten-Boot BJ; Lekkerkerker JF Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2644-5; author reply 2645-6. PubMed ID: 10028368 [No Abstract] [Full Text] [Related]
18. Erythematous maculopapular eruption due to rivastigmine therapy. Monastero R; Lopez G; Mannino M; Camarda R Am J Med; 2001 Nov; 111(7):583-4. PubMed ID: 11705442 [No Abstract] [Full Text] [Related]
19. Medications for the treatment of Alzheimer's disease. Lampley-Dallas VT J Okla State Med Assoc; 2001 Aug; 94(8):347-9. PubMed ID: 11515383 [TBL] [Abstract][Full Text] [Related]
20. [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]. Gasser US; Gasser T MMW Fortschr Med; 2001 Dec; 143(51-52):40-1. PubMed ID: 11824165 [No Abstract] [Full Text] [Related] [Next] [New Search]